Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Butylscopolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.78 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.76 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.76 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylscopolamine SCHEMBL1650352 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL25292 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL25291 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2441812 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL5028833 | 0.99 | BLM (0.98) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL16168163 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29643439 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2446869 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL14672547 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29473416 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132565-A1 | INDIVIDUALIZED THERAPEUTIC ANTICANCER VACCINE | Nykode Therapeutics ASA (NO) | 2023-02-15 | — | — | EP | claimed |
| EP-4303228-B1 | LONG-ACTING COAGULATION FACTOR VII AND METHODS OF PRODUCING SAME | OPKO BIOLOGICS LTD (IL) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026103808-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 苏州宜联生物医药有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12622912-B2 | Application of pyrido[1,2-a]pyrimidinone analog | Guangzhou Joyo Pharmatech Co., Ltd (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4729061-A1 | USE OF AKT INHIBITOR IN PREPARATION OF DRUG FOR PREVENTING OR TREATING BREAST CANCER | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097117-A1 | CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2026-04-09 | — | — | US | disclosed |
| US-20260091033-A1 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | INST NAT SANTE RECH MED (FR) | 2026-04-02 | — | — | US | disclosed |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4704915-A1 | LINKERS FOR DRUG CONJUGATES AND ANTIBODY DRUG CONJUGATES | BioAtla, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121586576-A | Application of AKT inhibitor in preparation of medicines for preventing or treating breast cancer | 南京正大天晴制药有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-3979830-A1 | PREBIOTIC FORMULATIONS FOR PREVENTION OF SEPSIS AND NECROENTEROCOLITIS INDUCED NEURODEVELOPMENTAL DEFICIENCIES | Research Institute at Nationwide Children's Hospital (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20220096645-A1 | POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3693737-B1 | METHOD AND SYSTEM FOR DETERMINING INTEGRATED METABOLIC BASELINE AND POTENTIAL OF LIVING CELLS | AGILENT TECHNOLOGIES INC (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3969116-A1 | ACTIVATABLE BISPECIFIC ANTIBODIES COMPRISING A LINKER BETWEEN THE TWO BINDING DOMAINS WHICH IS A HUMAN IMMUNOGLOBULIN HINGE REGION, OR A VARIANT THEREOF, AND USES THEREOF | LockBody Therapeutics Ltd (GB) | 2022-03-23 | — | — | EP | disclosed |
| EP-3971175-A1 | CRYSTAL FORM OF QUINAZOLINONE COMPOUND AND PREPARATION METHOD THEREFOR | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| US-20220079940-A1 | METHODS OF TREATING CANCERS | FOGHORN THERAPEUTICS INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3961742-A1 | ORGANIC SEMICONDUCTIVE LAYER COMPRISING PHOSPHINE OXIDE COMPOUNDS | Novaled GmbH (DE) | 2022-03-02 | — | — | EP | disclosed |
| CN-109908334-B | Tumor vaccine and preparation method and application thereof | 四川大学 | 2022-02-15 | — | — | CN | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220031696-A9 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | UNIVERSITÉ PARIS CITÉ (FR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097117-A1 | CONJUGATES | CRBN, CUL4B, CUL4A | CHRM2 1176/4885CHRM1 1268/4885CHRM5 1059/4885 |
| US-20260091033-A1 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | FGFR3, FGF23, FGFR2 | CHRM2 3054/4885CHRM1 3607/4885CHRM5 3329/4885 |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | NR0B2, NR0B1, ESRRA | CHRM2 1856/4885CHRM1 2131/4885CHRM5 1342/4885 |
| US-20220096645-A1 | POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY | TOP2A, TOP1, TOP2B | CHRM2 4585/4885CHRM1 4525/4885CHRM5 4699/4885 |
| US-12622912-B2 | Application of pyrido[1,2-a]pyrimidinone analog | PIK3CA, BRCA1, PIK3CD | CHRM2 4530/4885CHRM1 4092/4885CHRM5 4718/4885 |
| US-20220031696-A9 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | FGFR3, FGFR1, FGFR2 | CHRM2 4400/4885CHRM1 4626/4885CHRM5 4655/4885 |
| US-20220079940-A1 | METHODS OF TREATING CANCERS | MCL1, BRPF3, VHL | CHRM2 4866/4885CHRM1 4875/4885CHRM5 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.